Jun 8, 2026 · 7 min
AI optimism and obesity breakthroughs lift Nvidia and Lilly
Nvidia Up, Campbell's Gains, Eli Lilly Rises as 30% Weight Loss Sets High Bar for Obesity Drug Race
The episode connects Nvidia’s confidence in expanding AI demand with Eli Lilly’s clinical progress and Campbell Soup’s changing market position.
- 1Jensen Huang says the AI buildout remains in its early stages, supporting Nvidia’s stock rise.
- 2Campbell Soup delivered mixed earnings as it prepares to leave the S&P 500.
- 3Eli Lilly posted clinical data showing its next-generation obesity drug achieved 30% weight loss.
Don't miss
Eli Lilly’s new clinical data showing 30% weight loss sets a demanding benchmark for competing obesity drugs.
The brief
Nvidia shares rose after CEO Jensen Huang reassured investors that the AI buildout is still in its early stages, reinforcing the case for continued technology spending.
The episode then turns to Campbell Soup, where mixed earnings arrive alongside the company’s upcoming exit from the S&P 500, a symbolic shift in market standing.
Eli Lilly provides the strongest pharmaceutical signal: new clinical data for its next-generation obesity drug points to 30% weight loss and raises expectations across the category.
Taken together, the stories show markets rewarding credible growth narratives while reassessing companies facing tougher benchmarks, weaker momentum, or changing investor status.
Featuring
Jen-Hsun HuangMentioned
Listen to the full episode and explore every guest, topic, and moment on PodLume.